NOVADIP Biosciences S.A

Novadip Biosciences is a clinical-stage biopharmaceutical company founded to design, develop, and bring to the market a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. Novadips lead allogeneic product, NVD-X3, employs a matrix containing multiple bioactive factors that induce accelerated tissue healing. Designed as an off-the-shelf product, NVD-X3 can be shipped and stored at room temperature and offers superior intraoperative handling characteristics. Novadip is also developing NVD-003, an autologous therapy derived from ASCs as a potential single treatment to save limbs and restore mobility in patients with congenital pseudarthrosis of the tibia (CPT). CPT is a rare pediatric bone condition. Learn more about our technology platform and clinical development programs at www.novadip.com Phone number: +32/10 77 92 20 E-mail: info@novadip.com VAT: BE0535.575.602 Privacy policy: https://novadip.com/privacy-po...